|View printer-friendly version|
|December 17, 2001 11:41 a.m.|
|Teva Announces Final Approval of Lovastatin Tablets|
FEDERAL JUDGE INVALIDATES AN AUGMENTIN PATENT
Jerusalem, Israel, December 17, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received final FDA approval of its Abbreviated New Drug Application (ANDA) for Lovastatin Tablets 10, 20 and 40 mg, following the expiration of Merck's period of pediatric exclusivity for Mevacor. Teva had originally received approval in June 2001, but the FDA subsequently awarded six months pediatric exclusivity to Merck. Annual sales of Mevacor are estimated at approximately $200 million, and Teva will launch its Lovastatin tablets immediately.